Striving for 2023 launch, Pfizer touts topline PhIII win for another mass market vaccine

One of the vaccines that Pfizer has pegged for a 2023 launch has hit the mark in Phase III, setting up a filing by the end of the year.

MenABCWY, as the shot is known, is a pentavalent meningococcal vaccine candidate that combines two existing Pfizer vaccines — Trumenba and Menveo — in one. By formulating them together, the company says it could simplify the vaccination schedule with one vaccine that provides the broadest serogroup coverage of any out there.